Clinical Trial Update: Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib combined with sintilimab and SCRT in various unresectable advanced solid tumors, including biliary tract tumors, gastric ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Gastric Cancer
• Small Cell Lung Cancer
• Unresectable Advanced Solid Tumors

Drugs mentioned

• SCRT
• Sintilimab (sintilimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Unresectable Advanced Solid Tumors, Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN